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Of all cancer types breast cancer is the most common malignancy
in females. Women in Western countries have a lifetime risk of
about 10% to develop breast cancer and it is the leading cause of
death among women at 35–55 years of age (Harris et al, 1992).
About 5–10% of breast cancers are hereditary; a genetically and
clinically heterogeneous disease in which several susceptibility
genes, including BRCA1 and BRCA2, have been identified
(reviewed by Martin and Weber, 2000; Alberg and Helzlsouer,
1997; Paterson, 1998). 
BRCA1 encodes for a multifunctional protein which contributes
to homologous recombination and DNA damage repair, cell cycle
checkpoint control, embryonic proliferation, transcription regula-
tion and ubiquitination (reviewed by Deng and Scott, 2000;
Welcsh et al, 2000). The majority of the BRCA1 mutations result
in premature chain termination during protein translation, and
these are scattered over the entire coding region of the BRCA1
gene. Hence, inactivation of BRCA1 has been proposed to induce
a mutator phenotype which would accelerate tumour growth by
increasing genetic instability. Compared to sporadic cases, inher-
ited breast cancer cases from germline mutations in BRCA1 have a
number of distinctive clinical features such as an early age of onset,
a higher prevalence of bilateral breast cancer and the presence of
associated tumours, in particular ovarian cancer. Breast tumours
from BRCA1-carriers are more likely to be highly proliferative
and poorly differentiated (grade 3), also more frequently have an
atypical medullary-like appearance (Lakhani et al, 1998) with a
higher degree of lymphocyte infiltration and show an excess of
continuous pushing margins. Moreover these tumours are more
often oestrogen (ER) and progesterone (PgR) receptor and
cERBB2 negative and frequently show TP53 alterations, reviewed
by (Phillips et al, 1999). While these tumour features can be used
to estimate the likelihood that a breast tumour is caused by a
BRCA1 germline mutation it is not yet possible to distinguish a
BRCA1 mutated tumour by basic pathology. 
Gene expression analysis by cDNA (micro)arrays is a powerful
tool for characterizing the variation in transcriptional programs in
cells and tissues. Expression profiles of genes using mRNA from
breast tumour cell lines, grossly dissected tumours (Perou et al,
1999) or from laser capture microdissected cells from human
breast tumour tissues (Sgroi et al, 1999) have been generated. The
data revealed several clusters of co-expressed genes, some of
which could be connected to other cell types including stromal
cells and B lymphocytes. Although it is feasible to analyse gene
expression in microdissected tumour specimens, Ross (Ross et al,
2000) and Perou (Perou et al, 2000) showed that it is possible to
explore and to interpret some of the biology of surgical tumour
tissues by analysing these tumours intact. Thus, as in conventional
morphological pathology, one might be able to observe interac-
tions between a tumour and its microenvironment in this way.
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Summary About 5–10% of breast cancers are hereditary; a genetically and clinically heterogeneous disease in which several susceptibility
genes, including BRCA1, have been identified. While distinct tumour features can be used to estimate the likelihood that a breast tumour is
caused by a BRCA1 germline mutation it is not yet possible to categorize a BRCA1 mutated tumour. The aim of the present study is to
molecularly classify BRCA1 mutated breast cancers by resolving gene expression patterns of BRCA1 and matched sporadic surgical breast
tumour specimens. The expression profiles of 6 frozen breast tumour tissues with a proven BRCA1 gene mutation were weighed against
those from 12 patients without a known family history but who had similar clinico-pathological characteristics. In addition two fibroblast
cultures, the breast cancer cell-line HCC1937 and its corresponding B-lymphoblastoid cell line (heterozygous for mutation BRCA1 5382insC)
and an epithelial ovarian cancer cell line (A2780) were studied. Using a high density membrane based array for screening of RNA isolated
from these samples and standard algorithms and software, we were able to distinguish subgroups of sporadic cases and a group consisting
mainly of BRCA1-mutated breast tumours. Furthermore this pilot analysis revealed a gene cluster that differentially expressed genes related
to cell substrate formation, adhesion, migration and cell organization in BRCA1-mutated tumours compared to sporadic breast tumours. 
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Recent data imply that gene expression analysis with
(micro)arrays allows for tumour classification (Golub et al, 1999)
and possibly for prediction of prognosis (Alizadeh et al, 2000),
while Bittner et al (2000) discovered a subset of genes critical for
the metastatic process of melanomas. In accordance with these
observations, a relevant (sub)set of genes expressed in hereditary
cancers could aid in the distinction between BRCA1 gene mutated
and sporadic breast tumours. The aim of the present study is to
molecularly classify BRCA1 mutated breast cancers by resolving
gene expression patterns of BRCA1 and matched sporadic surgical
breast tumour specimens. 
MATERIALS AND METHODS 
Patients and samples 
Tumour specimens were selected from a pool of frozen specimens
(liquid nitrogen) originally submitted to our laboratory for steroid
hormone receptor analyses. Seven tumours had a previously estab-
lished germ-line mutation in the BRCA1 gene (F1-7). Of these
seven BRCA1 mutations three occurred at the BRCT domain (2
times 5382insC and 5396 +1G>A in samples F3,5,7). This domain
interacts with TP53 and functions as a transactivator in both TP53
dependent and independent ways. Sample F4 contained the large
genomic deletion encompassing exon 13 that occurs quite
frequently in the Dutch population. Two tumours had a 1411insT
alteration in exon 11 of the BRCA1 gene (F2,6). The latter exon
encodes for a domain that interacts with RAD 51 that is involved
in DNA damage repair. The 185insA mutation, in the N-terminus
of the BRCA1 gene, is within the RING finger domain. These
BRCA1 mutated breast tumours were matched to 15 sporadic
breast tumours from patients without a family history of breast
cancer (S1–15), for steroid hormone receptor status, tumour size,
differentiation grade, histology, age, menopausal and nodal status
of the patient. The information on family history was based on
retrospective chart review (the charts are computerized and
updated on a regular basis). The pathology data were extracted
from pathology reports and, in addition, all slides were reviewed
by a single pathologist. Other inclusion criteria were that frozen
tumour sample weight needed to be > 300 mg, with epithelial
tumour cells comprising at least 50% and available data on follow-
up. The median age of the patients was 37 years (range, 26–73
years) at time of primary surgery. Sixteen of the 22 patients had
breast-conserving therapy (lumpectomy) and six a modified
mastectomy. Eight patients were node positive. Six patients (27%)
received systemic adjuvant chemotherapy (cyclophosphamide,
methotrexate and 5-fluorouracil). Three patients were post-
menopausal. Tumour progression occurred in 12 patients and 8
patients died during follow-up. Of these 22 tumours, 19 had a poor
differentiation grade, 15 were larger than 2 cm (T2/T3), 15 were
ER negative and 11 had a TP53 mutation. Our study design was
approved by the medical ethical committee of the University
Hospital Rotterdam, the Netherlands and by our Cancer Centre
(protocol DDHK 91–17, updated in 1995). 
To establish a context for the interpretation of the variations in
expression patterns seen in the tumour samples we also included two
fibroblast cultures, the epithelial breast cancer cell line HCC1937
(hemizygous for the BRCA1 5382insC mutation) and its matching B-
lymphoblastoid cell line (heterozygous for this mutation; Tomlinson
et al, 1998), and the epithelial ovarian cancer cell line A2780. 
Assays of ER and PgR and analyses of TP53 and
BRCA1 gene status 
ER and PgR levels were determined in cytoplasmic extracts
(cytosols), routinely prepared according to procedures recom-
mended by the EORTC Breast Cancer Cooperative Group, with
ligand binding assays or with enzyme immunoassays (ER-EIA and
PgR-EIA, Abbott Laboratories, IL, USA), as described previously
(Foekens et al, 1989). For the study of TP53 mutations, exons 5–8
of the TP53 gene were analysed with SSCP and direct sequencing
and with immunological techniques, i.e. immunohistochemical
analyses using MAB 1801 and DO1 and the luminometric
immuno assay (LIA), as described previously (Berns et al, 1996;
Kuenen-Boumeester et al, 1999; Berns et al, 1998). Samples with
mutations observed by sequence analysis are designated as
‘mutated’ whereas samples in which an over-expression in the
tumour cells for both the anti-p53 mABs 1801 and DO1 was
observed, but without a mutation in exons 5–8, are designated as
‘IH > 80%’, i.e. altered (listed in Table 1). Twelve out of 23
samples are wild-type, a mutation was observed in 8 samples and
an over-expression (>80% of the tumour cells stained positive)
without mutation in exon 5–8 was observed in three cases. The
majority of the frozen sporadic breast tumours were tested for
BRCA1 protein expression, and BRCA1 gene alterations by DSDI
with subsequent sequencing of the altered BRCA1 gene fragment
(Papelard et al, 2000) and all samples were tested for 22 different
mutations, by allele specific oligonucleotide hybridization for
distinct mutations or by PCR for exon deletions, with a minor
modification, as described previously (Petrij-Bosch et al, 1997;
Peelen et al, 1997). This targeted analysis included the Dutch
founder mutations in BRCA1 and BRCA2 that at present account
for 60–70% of the germ-line mutations, i.e. 185insA, 185delAG,
1411insT, 1438delT, 2312del5, 2329delC, Q780X, 2765delTGC,
2804delAA, E908X, 2846del4, 2883del4, E1214X, 3938insG,
Q1281X, IVS12-1643del3835 (3.8 kb deletion of exon 13), 5396
+ 1 G >A, 5382insC, IVS21-36del510, IVS22 + 5G > A (deletion
of exon 22) in BRCA1, 5579insA and 6503delTT in BRCA2.
With respect to the sporadic tumours on 10 of the 15 samples a
full sequencing was done of the BRCA1 gene. All samples were
found to be wild-type, although in tumour sample S8 a polymor-
phism (S1436S, see Table 1) was observed. Targeted BRCA1
mutation analyses in the remaining five samples revealed no
alterations. 
RNA isolation, cDNA generation and array hybridization 
RNA was prepared from the frozen surgical tumour samples under
stringent conditions to avoid degradation and contamination.
Briefly: 26 frozen tissue sections, 50 µ m each, were cut with a
cryostat at – 20˚C. The first and last sections (5 µ m) were counter-
stained with H&E and the percentage of epithelial tumour cells
was estimated. Total RNA from tumour samples and cell lines was
extracted using RNAZolB (Campro Scientific, Veenendaal, The
Netherlands) described by Auffray (Auffray and Rougeon, 1980)
with a median total RNA recovery of 203 µ g (range 87–427 µ g).
RNA integrity was verified by agarose gel electrophoresis. The
RNA samples were treated with DNAse and genomic PCR
analyses, with intronic primers, for TP53 confirmed that no
residual DNA was present. These RNA samples (2–5 µ g) were
used to synthesize 32P-radiolabelled complex cDNA probes and
these fragments were hybridized overnight to the Clontech Atlas540 EMJJ Berns et al
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Human Cancer cDNA expression arrays according to the
manufacturer’s instructions (Clontech Corp., Palo Alto, CA;
http://www.clontech.com). These filters contain 588 cancer related
genes organized by their functional classes that are spotted in
duplicate. Membranes were subsequently washed and exposed to a
Phosphorlmaging screen for 1–7 days. 
Array data analysis 
Data were acquired and quantified using the Molecular Dynamics
Phospholmager and ImageQuant software (Molecular Dynamics,
Sunnyvale, CA, USA). The signals from the duplicate spots and
their reproducibility was verified by comparing these duplicate
spots using the AtlasImage V1.0 software (Clontech Corp., Palo
Alto, CA). The mean value and percentual deviation of the dupli-
cate spots was calculated. Subsequently, the median deviation of
20 randomly duplicate spots on each filter was estimated. The data
on the duplicate spots were highly reproducible since the overall
median value of the percentual deviation between these duplicate
spots of all filters was only 2% (range: 0.4–9%). When applicable
the data of the individual spots were corrected for excess
hybridization (‘bleeding’) of adjacent overpressed genes. The
background of each filter was determined by measuring the level
(amount of counts) in several ‘blank’ areas (i.e., no genes were
spotted in those areas) of the filter. Signals that were on average
1.5 times background level were considered too low for an accu-
rate measurement and were excluded from further analysis, thus
defined as negative/missing. As a consequence only those genes
with a 1.5 times expression above the background were considered
positive hybridizations and these were included in further array
data analyses. Moreover, when on the filter the expression of half
or more of the genes was below 1.5 times the background level
(i.e. negative/too low), the hybridization was considered as poor
and hence four arrays were excluded from further analyses. In
summary the criteria for inclusion of expression data in the final
analyses were that: (a) individual signal of a gene had to be greater
than 1.5 times that of the background level (defined as positive
hybridizations); (b) each tumour sample must show proper
hybridization, meaning that it had to be above 1.5 times the back-
ground, for at least 50% of all 588 genes analysed; and (c) each
single gene needed to be expressed above 1.5 times the back-
ground in at least 14 of the 18 breast tumour samples studied.
HER2/neu was for example excluded since it was expressed above
1.5 times the background in only 8 out of 18 samples and
FGF3/INT2 showed a positive hybridization in only 4 out of 18
samples. 
Hierarchical clustering was applied to the samples and the genes
using the cluster analysis software developed by Eisen (Eisen et al,
1998) (http://rana.stanford.edu/clustering) on spots that were
corrected for background. According to the recommendations,
hierarchical clustering was performed on the log-transformed and
normalized data set using an average linkage clustering and
Spearman rank correlation as similarity metric. Data are available
upon request. The resulting outcome was displayed with the
TreeView program (Eisen et al, 1998). The log-transformed data
of each gene relative to its median expression level were visualized
as a colour: red represented expression above the median, black
represented the median and green indicated expression less than
the median. The colour intensities indicate the magnitude of the
deviation from the median and reflect the level of expression. Grey
specified gene expression data that were missing (see above).
Rows represented genes and columns the experimental samples. 
RESULTS 
Tumours and arrays 
The expression profiles (portraits) of frozen breast tumour tissues
with a proven BRCA1 gene mutation (F) were weighed against
those from patients without a known family history (S) and a
BRCA1 mutation but which had similar clinico-pathological char-
acteristics. For this exploratory analysis we used the Atlas Human
Cancer cDNA Expression Arrays. Four samples, out of the initial
22 breast tumour samples studied, were excluded since the
hybridization results did not fulfil the criteria, i.e. not above 1.5
times the background for at least 50% of all 588 genes analysed
(samples F7, S5–7). Thus the profiles of 6 frozen breast tumour
tissues with a proven BRCA1 gene mutation and of 12 samples
without BRCA1 gene mutation and of 1 control cell-line,
HCC1937, were weighed. In order to identify patterns of gene
expression in the remaining 18 breast tumour specimens (listed in
Table 1) we have used the hierarchical clustering method. Of the
588 genes studied, 248 were not included in the final analysis since
these genes did not show a hybridization level of 1.5 times above
the background in 14 of the 18 tumour samples analysed (Eisen
et al, 1998). The overall similarity in gene expression patterns of
this basic set generates a dendrogram of tumour specimens in
which the pattern and length of the branches reflects the relatedness
of the samples. Two differentially expressed genes, integrin beta 4
and HPRT were validated using a different methodology, i.e. RT-
PCR on a subset of tumours, and these RT-PCR results confirmed
the outcome of the cDNA array data (not shown). 
Clustering of tumours 
Each tumour showed a remarkable variation in its gene expression
pattern, as seen in Figure 1. Two distinct main groups with close
overall similarity were detectable. The first group, including seven
samples, i.e. S1, 4,8–11 and F1, consisted primarily of sporadic
tumours (Figure 1, tumour group A). Sample ‘F1’ was a second
tumour from a BRCA1 mutation carrier in the contralateral breast
(see Table 1). This patient received adjuvant chemotherapy for the
primary tumour which may have altered the characteristics of the
analysed second primary tumour. The second closely related group
of tumours based on the lengths of the branches of the dendro-
gram, i.e. F2-6 and S2 + 3, consisted mainly of BRCA1 mutated
tumours. Samples S12 + 13 and S14 + 15 were, although less
related, both attached to this less homogeneous cluster (Figure 1
and Table 1, tumour group B). Group B also contained the epithe-
lial breast tumour cell-line HCC1937, which is hemizygous for the
BRCA1 mutation 5382insC. 
Subsequently, patient and tumour characteristics were related to
the outcome of the clustering. The data are listed in Table 1 and are
given according to the outcome of the dendrogram shown in
Figure 1. Group A represents tumours from patients that were
mainly node negative (NO, 6 out of 7 patients) whereas 5 out of 11
patients were node positive (N +) in group B. There was no differ-
ence between the medium time of follow-up of patients alive in
both subgroups (83 months in group A versus 76 months in group
B) or the occurrence of metastasis or double primaries. Less
patients were alive in group A (4 out of 7 patients) compared to
group B (8 out of 11 patients, Table 1). With respect to tumour
characteristics, the TP53 gene was more often altered in group B542 EMJJ Berns et al
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(5 out of 11 tumours in group B compared with 2 out of 7 tumours
in group A). None of the other clinico-pathological factors were
related with the clustering of the tumours (Table 1). 
Subsets of clustered genes 
The genes were also divided into two main clusters. Cluster I depicts
genes that were relatively highly expressed in tumour group A and
expressed at a lower level in group B (see Figure 1). Within group I
a small subset of genes was chosen which showed comparable
expression profiles in all samples (correlation coefficient = 0.77).
This small cluster, designated 1.1, contains 36 of the 340 displayed
genes. It comprises many genes whose products are related to or
necessary for DNA damage response and repair (i.e. XRCC1,
ERCC1&5, ssDNA binding protein our alpha), for apoptosis (Bax,
caspases 2&7, TRADD, CRAF1, FAST kinase) or for cell cycle
and growth regulation (MAPK 1, MAPK/ERK kinases 1 and -6,
MEKK, p57KIP2, STAT5B, cdc25A and -B, cyclins D1 and C).
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Figure 1 Overview of gene expression profiles of BRCA1 mutated and sporadic breast tumours. Left panel shows the relative expression levels of 340 genes,
given in rows, from 19 samples, in columns, in a cluster diagram overview. (F1–6; six tumour samples with a BRCA1 mutation, HCC(log): an epithelial tumor
cell-line, HCC1937 grown at confluence, with a BRCA1 mutation and S1–5 and 8–15: 12 sporadic tumour samples). The expression of log transformed data of
each gene relative to its median expression level is visualized as a colour: red representing expression greater than the median, green representing expression
less than the median, black representing the median. Grey indicates technically inadequate or background data. The colour intensities represent the magnitude
of the deviation from the median and reflect the level of expression. The distinctive molecular profiles of each tumour provides a basis for sub-classification. The
hierarchical clustering, which depicts genes and samples according to similarity in their overall expression patterns, reveals the tissue samples in sub-groups of
sporadic cases and a group that mainly consists of BRCA1 mutated cases, i.e. tumours F2–6. An expanded view of two sets of differentially expressed genes,
i.e. cluster I.1 and cluster II.1 is shown in panels at the right. The marked genes (CK14, EGF-R, Bax, Cyclin D1, and XRCC1, p57, MAPKK) are discussed in
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Furthermore, receptors (IGFIIR, EGFR, IGFBP4, TGFbetaRIII)
and several cell fate and development related genes were relatively
over-expressed in this cluster. Within this cluster 1.1 the DNA
repair gene XRCC1, the cyclin dependent inhibitor p57KIP2 and
the MAP kinase kinase were closely correlated (P = 0.95). The
relatively high expression of the cytoskeletal 14 keratin in the
tumour samples in group A points to a myoepithelial (basal) cell
origin. 
Cluster II comprises genes that were relatively lower
expressed in tumour group A compared to group B. For example,
the DNA mismatch repair gene MSH2, the tumour suppressor
gene APC, the TP53 regulated protein MDM2, K-RAS and several
invasion/adhesion associated genes were under-represented as
compared to the B group (cluster II.1). Furthermore, we recognized
a subset of genes that might characterise the BRCA1 mutated
tumour types (Figure 2). This subset (correlation coefficient =
0.81; cluster 11.2) contains genes as vitronectin precursor,
different collagens, laminin and fibronectin, which have been
related to cell substrate formation, adhesion, migration and cell
organization. To establish a context for the interpretation of the
variations in expression patterns seen in the tumour samples, we
additionally characterized two fibroblast cultures, the HCC1937
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Figure 2 An expanded view of a set of differentially expressed genes in the BRCA1 mutated tumours is shown for the samples included in Figure 1 and for all
samples tested. Upper panel shows an expanded view of cluster II.2, containing genes with relatively high expression levels in BRCA1 mutated tumours, from
Figure 1. To provide a tissue type framework for the analysis of the variations in expression patterns, two fibroblast cultures, the epithelial breast cancer cell line
HCC1937 and its corresponding B-lymphoblastoid cell line and an epithelial ovarian cancer cell line (A2780, which has also been cultured in the presence of
cisplatin; A2780cis) were included in the advanced analysis. The overall characteristics of this clustering were very similar to those of Figure 1 and only minor
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corresponding B-lymphoblastoid cell line (heterozygous for
mutation BRCA1 5382insC) and an epithelial ovarian cancer cell
line (A2780). The outcome of this separate clustering analysis
showed a slightly altered clustering of tumour samples and genes
(Figure 2) but despite this suggested that the expression of the set
of genes characteristic of adhesion and migration was a feature
shared by these BRCA1 mutated tumour samples and the
cultured fibroblasts. The percentage of epithelial tumour cells in
the tumours in cluster A and B is, however, similar (Table 1).
These data demonstrated that these BRCA1-tumour associated
genes were higher expressed in fibroblast cultures but not in the
epithelial ovarian and breast tumour cell lines (Figure 2). 
DISCUSSION 
Breast cancer is a multifactorial and heterogeneous disease and
further understanding of its biology is important. Many genes and
signalling pathways controlling cell proliferation, differentiation
and death, as well as genomic integrity have been reported to be
involved. The aim of the present study was to use arrays as a tool to
understand and classify BRCA1 mutated tumours based upon their
global gene expression patterns. The expression profiles of six
surgical frozen breast tumour samples and one epithelial cell-line
from patients with an inherited BRCA1 gene mutation were
compared with the profiles from 12 patients without a family history
and without BRCA1 gene alterations. A hierarchical clustering
method was used to group the variation in mRNA levels of genes.
We identified two major tumour groups. Group A represented
tumours from patients that were mainly node negative and had fewer
TP53 gene alterations with less patients alive during follow-up.
Genes that were highly expressed in group A include cytokeratin 14,
in which expression has been related to myoepithelial (basal) cells
(Otterbach et al, 2000). Interestingly, this cluster also included
genes whose expression patterns have been characterized by
previous studies to be related to breast cancer prognosis (i.e. BAX,
cyclin D1 and EGFR). Thus the EGF-receptor is highly expressed
in this group of mainly ER-negative or ER-low cells. An inverse
correlation of the level of EGFR and ER has been reviewed (Klijn
et al, 1992). Recent data showed that in ER-negative or low cells
NF-kappaB is increased by EGFR. The NF-kappaB on its turn
transactivates the cell cycle regulator protein cyclin D1 which
causes increased phosphorylation of RB, allowing for cell-cycle
progression, more strongly in ER-negative cells (Biswas et al,
2000). This may indicate a specific group of ER-negative tumour
cells with increased EGFR and cyclin D levels. 
Interestingly, group B isolates five out of the six BRCA1
mutated tumours into a distinct sub-set. Only tumour F1 was posi-
tioned in group A. The latter tumour, however, was a second
primary tumour from a BRCA1 mutation carrier (185insA) that
emerged 57 months after primary surgery in the contralateral
breast. The patient had recieved adjuvant chemotherapy (CMF)
after surgery of the first primary tumour, which may have affected
the characteristics of this second primary tumour. Tumours S2 and
S3 that were also included in this sub-group did not show a
BRCA1 mutation after complete sequence analysis. Breast cancers
without a BRCA1 germline mutation but which nevertheless
exhibit BRCA1 under-expression may have similar pathologic
characteristics to breast cancers from BRCA1 germline mutation
carriers (Wilson et al., 1999). We have therefore analysed
the BRCA1 protein expression, using immunohistochemical
techniques, but did not find any relation to the BRCA1 expression
levels and clustering of the tumours. The BRCA2 gene hybridiza-
tion data were extracted from the filter arrays and again no relation
was observed between the expression levels of BRCA2 and
clustering outcome. It is however still possible that gross genomic
alterations, which cannot be detected by sequence analysis, have
altered the BRCA1 gene or that BRCA2 gene mutations or muta-
tions in other as yet undiscovered major breast cancer predisposing
genes could be involved in these cases. 
Examination of the gene expression profiles revealed a sub-set
of genes may characterize the BRCA1 tumour types, i.e. vitro-
nectin precursor, different collagens, laminins and fibronectin,
which have been related to cell substrate formation, adhesion,
migration and cell organization. Of these, fibronectin expression
has been reported to be related to normal but not to mammary
epithelial cells (Lee et al, 1991). Supplementary cluster analysis
showed that these genes appear to be highly expressed in fibroblast
but not in the two epithelial breast and ovarian tumour cell-lines.
Thus expression of a set of genes characteristic of adhesion and
migration was a feature shared by these BRCA1 mutated tumour
samples and cultured fibroblasts. Interestingly, the expression of a
set of genes characteristic of stromal cells, including collagen, has
been reported to be a feature shared by breast tumour samples and
the so as such described ‘stromal-like’ mammary tumour cell-lines
Hs578T and BT549 (Perou et al, 2000). As a consequence, the
authors suggested that the expression pattern seen in the tumour
samples is likely to be due to the stromal component of the tumour.
An explanation for the unexpected expression pattern observed in
the present study could be the different growth patterns observed in
BRCA1 associated tumours when compared to sporadic tumours,
which is characterized by an excess of continuous pushing margins
in the BRCA1 mutated tumours with fibroblasts that are highly
active (reviewed by Philips et al, 1999). The latter finding will be a
subject of future investigation. These markers may aid in the recog-
nition of BRCA1 mutated tumours. 
Although the sample size in any of the subgroups is too small to
support firm statistical analyses, our preliminary data show the
potential of gene expression based subtyping of breast tumours.
Advanced gene expression profiling, recently used by Hedenfalk
et al (2001), on glass cDNA arrays containing thousands of genes
which allows for the internal calibration of the expression data, is
preferred to identify the genes and profiles that matter for the
molecular pathogenesis pathways of hereditary cancers. This may
provide information on tumour response and possibly new targets
for breast cancer prevention and therapy. 
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